.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Federal Trade Commission
Moodys
AstraZeneca
Dow
Johnson and Johnson
Healthtrust
Deloitte
Harvard Business School
Covington

Generated: November 24, 2017

DrugPatentWatch Database Preview

Eluxadoline - Generic Drug Details

« Back to Dashboard

What are the generic sources for eluxadoline and what is the scope of eluxadoline patent protection?

Eluxadoline
is the generic ingredient in one branded drug marketed by Allergan Holdings and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eluxadoline has one hundred and fourteen patent family members in thirty-five countries and six supplementary protection certificates in five countries.

One supplier is listed for this compound.

Summary for eluxadoline

Pharmacology for eluxadoline

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: eluxadoline

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,994,206Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid► Subscribe
8,859,604Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid► Subscribe
8,609,865Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: eluxadoline

Country Document Number Estimated Expiration
Israel229444► Subscribe
Taiwan200539876► Subscribe
European Patent Office2573068► Subscribe
Japan2016516694► Subscribe
South Korea20150080006► Subscribe
Spain2428008► Subscribe
Japan2007529527► Subscribe
Japan5870220► Subscribe
Hong Kong1141519► Subscribe
TaiwanI361069► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ELUXADOLINE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017005Lithuania► SubscribePRODUCT NAME: ELUKSADOLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINAS ENANTIOMERAS, DIASTEREOMERAS, RACEMATAS ARBA DRUSKA; REGISTRATION NO/DATE: EU/1/16/1126 20160919
2017000010Germany► SubscribePRODUCT NAME: ELUXADOLIN; REGISTRATION NO/DATE: EU/1/16/1126 20160919
90007-7Sweden► SubscribePRODUCT NAME: ELUXADOLINE OR A PHARMACEUTICALLY ACCEPTABLE ENANTIOMER, DIASTEREOMER, RACEMATE OR SALT THEREOF; REG. NO/DATE: EU/1/16/1126 20160921
0865Netherlands► SubscribePRODUCT NAME: ELUXADOLINE OF EEN FARMACEUTISCH AANVAARDBAAR ENANTIOMEER,DIASTEREOMEER, RACEMAAT OF ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/16/1126 20160921
2017000009Germany► SubscribePRODUCT NAME: ELUXADOLIN ODER EIN PHARMAZEUTISCH AKZEPTABLES ENANTIOMER, DIASTEREOMER, RACEMATE ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1126 20160919
2017 00008Denmark► SubscribePRODUCT NAME: ELUXADOLIN ELLER EN FARMACEUTISK ACCEPTABEL ENANTIOMER, DIASTEREOMER, RACEMAT ELLER SALT DERAF; REG. NO/DATE: EU/1/16/1126 20160921
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Cipla
Cantor Fitzgerald
Boehringer Ingelheim
Fuji
Covington
Dow
US Army
Queensland Health
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot